Cáncer de tiroides. En búsqueda del tratamiento ... - ResearchGate

CÁNCER DE TIROIDES 513
cades (1940-1999): temporal trends in initial therapy
and long-term outcome in 2444 consecutively treated
patients. World J Surg 2002; 26: 879-85.
51. Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM.
Intermediate and long-term side effects of high-dose
radioiodine therapy for thyroid carcinoma. J Nucl Med
1998; 39: 1551-4.
52. Van Nostrand D, Neutze J, Atkins F. Side effects of
“rational dose” iodine-131 therapy for metastatic welldifferentiated
thyroid carcinoma. J Nucl Med 1986; 27:
1519-27.
53. Van Nostrand D. Sialoadenitis secondary to ¹³¹I therapy
for well-differentiated thyroid cancer. Oral Dis 2011; 17:
154-61.
54. Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising
incidence of second cancers in patients with low-risk
(T1N0) thyroid cancer who receive radioactive iodine
therapy. Cancer 2011; 117: 4439-46.
55. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve
DC, Tward JD. The risk of second primary malignancies
up to three decades after the treatment of differentiated
thyroid cancer. J Clin Endocrinol Metab
2008; 93: 504-15.
56. Sawka AM, Thabane L, Parlea L, et al. Second primary
malignancy risk after radioactive iodine treatment for
thyroid cancer: a systematic review and meta-analysis.
Thyroid 2009; 19: 451-7.
57. Podnos YD, Smith DD, Wagman LD, Ellenhorn JD. Survival
in patients with papillary thyroid cancer is not affected
by the use of radioactive isotope. J Surg Oncol
2007; 96: 3-7.
58. Pelizzo MR, Boschin IM, Toniato A, et al. Papillary
thyroid microcarcinoma (PTMC): prognostic factors,
management and outcome in 403 patients. Eur J Surg
Oncol 2006; 32: 1144-8.
59 DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural
history, treatment, and course of papillary thyroid
carcinoma. J Clin Endocrinol Metab 1990; 71: 414-24.
60. Tsang RW, Brierley JD, Simpson WJ, Panzarella T,
Gospodarowicz MK, Sutcliffe SB. The effects of surgery,
radioiodine, and external radiation therapy on the
clinical outcome of patients with differentiated thyroid
carcinoma. Cancer 1998; 82: 375-88.
61. Sacks W, Fung CH, Chang JT, Waxman A, Braunstein
GD. The effectiveness of radioactive iodine for treatment
of low-risk thyroid cancer: a systematic analysis
of the peer-reviewed literature from 1966 to April 2008.
Thyroid 2010; 20: 1235-45.
62. Lo CY, Chan WF, Lam KY, Wan KY Optimizing the treatment
of AMES high-risk papillary thyroid carcinoma.
World J Surg 2004; 28: 1103-9.
63. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches
to primary therapy for papillary and follicular
thyroid cancer. J Clin Endocrinol Metab 2001; 86: 1447-63.
64. DeGroot LJ, Kaplan EL, Shukla MS, Salti G, Straus FH.
Morbidity and mortality in follicular thyroid cancer. J
Clin Endocrinol Metab 1995; 80: 2946-53.
65. Martins RG, Caplan RH, Lambert PJ, Rooney B, Kisken
WA. Management of thyroid cancer of follicular cell
origin: Gundersen/Lutheran Medical Center. J Am Coll
Surg 1997; 185: 388-97.
66. Herrera MF, López-Graniel CM, Saldaña J, et al. Papillary
thyroid carcinoma in Mexican patients: clinical aspects
and prognostic factors. World J Surg 1996; 20: 94-9.
67. Palme CE, Waseem Z, Raza SN, Eski S, Walfish P,
Freeman JL. Management and outcome of recurrent
well-differentiated thyroid carcinoma. Arch Otolaryngol
Head Neck Surg 2004; 130: 819-24.
68. Sawka AM, Brierley JD, Tsang RW, et al. An updated
systematic review and commentary examining the effectiveness
of radioactive iodine remnant ablation in
well-differentiated thyroid cancer. Endocrinol Metab
Clin North Am 2008; 37: 457-80.
69. Robbins RJ, Tuttle RM, Sonenberg M, et al. Radioiodine
ablation of thyroid remnants after preparation with recombinant
human thyrotropin. Thyroid 2001; 11: 865-9.
70. Robbins RJ, Larson SM, Sinha N, et al. A retrospective
review of the effectiveness of recombinant human TSH
as preparation for radioiodine thyroid remnant ablation
(brief communication). J Nucl Med 2002; 43: 1482-8.
71. Pacini F, Molinaro E, Castagna MG, et al. Ablation of
thyroid residues with 30 mCi 131 I: a comparison in thyroid
cancer patients prepared with recombinant human
TSH or thyroid hormone withdrawal. J Clin Endocrinol
Metab 2002; 87: 4063-8.
72. Pitoia F, Degrossi OJ, Niepomniszcze H. Why should
the radioiodine dose be different in patients with differentiated
thyroid carcinoma prepared with recombinant
human TSH Eur J Nucl Med Mol Imaging 2004; 31:
924; author reply: 924-5.
73. Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment
with 30 mCi after recombinant human thyrotropin stimulation
in thyroid cancer: effectiveness for postsurgical
remnants ablation and possible role of iodine content in
L-thyroxine in the outcome of ablation. J Clin Endocrinol
Metab 2003; 88: 4110-5.
74. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine
ablation of thyroid remnants after preparation with
recombinant human thyrotropin in differentiated thyroid
carcinoma: results of an international, randomized, controlled
study. J Clin Endocrinol Metab 2006; 91: 926-32.
75. Pitoia F, El Tamer E, Schere DB, Passerieu M, Bruno OD,
Niepomniszcze H. Usefulness of recombinant human
TSH aided radioiodine doses administered in patients
with differentiated thyroid carcinoma. Medicina (B Aires)
2006; 66: 125-30.
76. Pilli T, Brianzoni E, Capoccetti F, et al. A comparison
of 1850 MBq (50 mCi) and 3700 MBq (100 mCi)
131-iodine administered doses for recombinant TSHstimulated
postoperative thyroid remnant ablation in
differentiated thyroid cancer. J Clin Endocrinol Metab
2007; 92: 3542-6.
77. Chianelli M, Todino V, Graziano FM, et al. Low-activity
(2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation
in thyroid cancer: comparison between hormone
withdrawal and use of rhTSH in low-risk patients. Eur
J Endocrinol. 2009; 160: 431-6.
78. Pitoia F, El Tamer E, Salvai ME, Niepomniszcze H. Protocol
for thyroid remnant ablation after recombinant TSH in
thyroid carcinoma. Medicina (B Aires) 2009; 69: 148-52.
79. Hänscheid H, Lassmann M, Luster M, et al. Iodine biokinetics
and dosimetry in radioiodine therapy of thyroid
cancer: procedures and results of a prospective
international controlled study of ablation after rhTSH
or hormone withdrawal. J Nucl Med 2006; 47: 648-54.
80. Rosário PW, Borges MA, Purisch S. Preparation with
recombinant human thyroid-stimulating hormone for
thyroid remnant ablation with 131 I is associated with
lowered radiotoxicity. J Nucl Med 2008; 49: 1776-82.
81. Mallick U, Harmer C, Yap B, et al. Ablation with low-dose
radioiodine and thyrotropin alfa in thyroid cancer. N
Engl J Med 2012; 366: 1674-85.
82. Schlumberger M, Catargi B, Borget I et al. Strategies
of radioiodine ablation in patients with low-risk thyroid
cancer. N Engl J Med 2012; 366: 1663-73.
83. Alexander EK, Larsen PR. Radioiodine for thyroid canceris
less more N Engl J Med 2012; 366: 1732-3.